Nontargeted metabolomics uncovering metabolite signatures in glioblastoma: a preliminary study on candidate biomarker discovery for IDH subtyping and survival prediction
This exploratory study identified potential metabolic biomarkers for GBM subtyping and prognosis prediction. However, further validation in large-scale clinical studies and mechanistic investigations are needed to confirm their applicability and reliability.
Authors
- Zeng-Rong Dong (ORCID: https://orcid.org/0009-0004-7223-7266)
- Zhipeng Su (ORCID: https://orcid.org/0000-0002-0794-4122)
- Peng Xu (ORCID: https://orcid.org/0000-0002-0999-8546)
- Xiling Chen (ORCID: https://orcid.org/0009-0007-4941-4705)
- Qun Li (ORCID: https://orcid.org/0000-0003-0869-6922)
- Qifan Zhang (ORCID: https://orcid.org/0009-0001-1561-2961)
- Kui Fang
- Ji Zhu
Institutions
- Wenzhou Medical University (CN)
- First Affiliated Hospital of Wenzhou Medical University (CN)
- The Third Affiliated Hospital of Zhejiang Chinese Medical University (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-05-08
- DOI
- https://doi.org/10.3389/fonc.2025.1568040
- Citations
- 1
- Primary Topic
- Metabolomics and Mass Spectrometry Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.81
Funders
- Wenzhou Medical University
- Fudan University
- State Key Laboratory of Genetic Engineering
- Natural Science Foundation of Zhejiang Province